ARS Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
SPRY$2.79+5.3%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets
(in thousands, except par value and share amounts)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $24,321 | $41,317 |
| Short-term investments | 176,648 | 203,669 |
| Accounts receivable, net | 28,662 | 25,347 |
| Inventories | 8,817 | 8,369 |
| Prepaid expenses and other current assets | 6,788 | 6,194 |
| Total current assets | 245,236 | 284,896 |
| Inventories, noncurrent | 23,221 | 23,053 |
| Property, plant and equipment, net | 2,285 | 2,465 |
| Intangible assets, net | 14,176 | 14,452 |
| Other assets | 2,653 | 2,786 |
| Total assets | $287,571 | $327,652 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities (including related party amounts of $1,431 and $1,624, respectively) | $48,263 | $37,948 |
| Contract liability, current | 757 | 609 |
| Other current liabilities | 592 | 588 |
| Total current liabilities | 49,612 | 39,145 |
| Term loans, net (including related party amounts of $4,826 and $4,819, respectively) | 96,522 | 96,374 |
| Financing liability | 74,673 | 72,140 |
| Contract liability, net of current portion | 978 | 1,130 |
| Other accrued liabilities | 4,478 | 4,605 |
| Total liabilities | 226,263 | 213,394 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value per share; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; 99,300,137 and 99,290,926 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 10 | 10 |
| Additional paid-in capital | 416,615 | 408,726 |
| Accumulated other comprehensive (loss) gain, net | (96) | 125 |
| Accumulated deficit | (355,221) | (294,603) |
| Total stockholders’ equity | 61,308 | 114,258 |
| Total liabilities and stockholders’ equity | $287,571 | $327,652 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.